Colice, GenePrice, DavidGerhardsson de Verdier, MariaRabon-Stith, KarmaAmbrose, ChristopherCappell, KatherineIrwin, Debra E.Juneau, PaulVlahiotis, AnnaRespiratory Effectiveness Group (REG)2017-12-062017-12-062017-12-01Colice, G, Price, D, Gerhardsson de Verdier, M, Rabon-Stith, K, Ambrose, C, Cappell, K, Irwin, D E, Juneau, P, Vlahiotis, A & Respiratory Effectiveness Group (REG) 2017, 'The effect of DPP-4 inhibitors on asthma control : an administrative database study to evaluate a potential pathophysiological relationship', Pragmatic and Observational Research, vol. 2017, no. 8, pp. 231-240. https://doi.org/10.2147/POR.S1440181179-7266http://hdl.handle.net/2164/9730Acknowledgments The authors acknowledge Koustubh Ranade (MedImmune, Gaithersburg, MD, USA) and Stephen Johnston, a member of the steering committee who was employed by Truven Health Analytics at the time the study was conducted, for their contributions to this study . Truven Health Analytics, an IBM Company, received funding from AstraZeneca in relation to this study. This work was previously presented as a poster at the annual international conference of the American Thoracic Society, May 19–24, 2017, Washington, DC (Colice G, et al. The Effect of Dipeptidyl-Peptidase-4 Inhibitors on Asthma Control: An Administrative Database Study to Evaluate a Potential Pathophysiological Relationship. Am J Respir Crit Care Med. 2017;195:A3050).10263893engSDG 3 - Good Health and Well-beingasthma controlDPP-4itype 2 diabetesR Medicine (General)R1Journal article10.2147/POR.S1440188